Cabinet approves signing of MoU between India, Suriname in field of Medical Products Regulation

The purpose of this Memorandum of Understanding is to facilitate a constructive dialogue on the laws and regulations pertinent to medical products as well as other relevant matters.

The MoU seeks to establish a framework for fruitful cooperation and exchange of information between the Centra! Drugs Standard Control Organization (CDSCO) and Ministry of Health, Government of the Republic of Suriname in matters relating to Medical products regulation in line with their international responsibilities. The main areas of cooperation between the two Regulatory Authorities include the following:

1. Promoting an understanding between the Parties of each other's regulatory framework, requirements and processes and facilitating future regulatory strengthening initiatives for both Parties,
2. Exchange of information and cooperation on Good Laboratory Practices (GLP), Good Clinical Practices (GCP), Good Manufacturing Practices (GMP) and Good Pharmacovigilance Practices (GPvP).
3. Recognition of Indian Pharmacopoeia
4. Exchange of safety information, including Pharmacovigilance, and adverse events where there is a particular safety concern related to the other Party. This includes safety concerns relating to medicines and medical devices.
5. Participation in scientific and practical conferences, symposiums, seminars and forum organized by the Parties.
6. Capacity building in mutually agreed areas,
7. Coordination at the international fora,
8. Any others areas of common interest.

The MoU will facilitate export of medical products leading to foreign exchange earnings. This would be a step towards an Atmanirbhar Bharat.

Convergence in the regulatory practices could help in increasing export of medicines from India and consequentially could help in better employment opportunities for educated professionals in the pharma sector.

The signed MoU between the regulatory authorities of the two countries will facilitate better understanding of medical products regulation with regard to pharmaceuticals including raw materials for pharmaceutical use, biological products, medical devices and cosmetic products.

The MoU will promote exchange of information and cooperation in areas pertinent to medical products and relevant administrative and regulatory matters within the jurisdiction of the parties.